Abstract: Energy systems and energy supply methods are described. In one aspect, an energy system includes a bus system configured to conduct electrical energy, a plurality of input adapters electrically coupled with the bus system and configured to electrically couple with a plurality of respective source entities which are individually configured to provide electrical energy, a plurality of output adapters electrically coupled with the bus system and configured to electrically couple with a plurality of respective consuming entities which are individually configured to consume electrical energy, and control circuitry configured to control individual ones of the input adapters to provide electrical energy from respective ones of the source entities to the bus system and to control individual ones of the output adapters to provide electrical energy from the bus system to respective ones of the consuming entities.

Abstract: Energy systems and energy storage system charging methods are described. In one aspect, an energy storage system charging method includes applying an excitation signal to a stator of an induction machine, outputting electrical energy from the stator of the induction machine during the applying, and charging an energy storage system using the electrical energy outputted from the stator.

Abstract: The invention provides methods and compositions for the treatment of primary, metastatic, and residual cancer in mammals, and more particularly, the use of materials such as whole cells and derivatives and portions thereof to stimulate the immune system to attack cancer.

Abstract: This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the mammal or human afflicted with cancer to mount an attack against the tumour lesion. In particular, the invention pertains to the use of whole-cells, derivatives and portions thereof with or without vaccine adjuvants and/or other accessory factors. More particularly, this disclosure describes the use of particular combinations of whole-cells and derivatives and portions thereof that form the basis of treatment strategy.

Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells.

Abstract: There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The manifold is arranged such as to delay the emptying of the medicament powder from the blister pocket.

Abstract: The invention here relates to a product comprised of a cell line or lines intended for use as an allogeneic immunotherapy agent for the treatment of cancer in mammals and humans. All of the studies of cell-based cancer vaccines to date have one feature in common, namely the intention to use cells that contain at least some TSAs and/or TAAs that are shared with the antigens present in patients' tumor. In each case, tumor cells are utilized as the starting point on the premise that only tumor cells will contain TSAs or TAAs of relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells as the basis of an allogeneic cell cancer vaccine. Normal cells do not possess TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines.

Abstract: A leg wrap structure is provided in a disposable absorbent garment such as a diaper or training pants. The leg wrap structure has a base layer, a top layer, and an elastic construction disposed therebetween. The elastic construction includes a plurality of spaced apart (e.g. generally equally spaced apart) elastic elements (e.g. strands or threads) that are aligned in a generally in generally parallel relation. Further, the top and base layers define a region of inelasticity. The leg wrap structure provides for the efficient formation of a reservoir and a plurality of fluid dams each capable of capturing a quantity of fluid to minimize the occurrence of fluid leaks from the absorbent article. Methods of forming such absorbent articles are disclosed.

Abstract: There is provided a blister form medicament pack comprising (a) a base sheet in which blisters are formed to define pockets therein for the containment of inhalable medicament; and (b) a lid sheet which is sealable to the base sheet except in the region of the blisters and mechanically peelable from the base sheet to enable release of said inhalable medicament. The base sheet and/or said lid sheet have a laminate structure comprising (a) a first layer of aluminum foil; and (b) a second layer of polymeric material of thickness from 10 to 60 micron, said polymeric material having a water vapor permeability of less than 0.6 g/(100 inches2) (24 hours) (mil) at 25° C.

Abstract: A sensor assembly for a gas turbine engine includes a telemetry module mounted at a rotor bearing compartment for sensing engine operational parameters and a cooling system for cooling the telemetry module separate from a rotor bearing lubricant flow.

Abstract: A leg wrap structure is provided in a disposable absorbent garment such as a diaper or training pants. The leg wrap structure has a base layer, a top layer, and an elastic construction disposed therebetween. The elastic construction includes a plurality of spaced apart (e.g. generally equally spaced apart) elastic elements (e.g. strands or threads) that are aligned in a generally in generally parallel relation. Further, the top and base layers define a region of inelasticity. The leg wrap structure provides for the efficient formation of a reservoir and a plurality of fluid dams each capable of capturing a quantity of fluid to minimize the occurrence of fluid leaks from the absorbent article. Methods of forming such absorbent articles are disclosed.

Abstract: There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The chimney is arranged to create turbulence in the airflow at the open blister pocket.

Abstract: There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The chamber is arranged to promote break up of said entrained medicament powder by exposing the entrained medicament powder to one or more regions of differential force during its transport through the chamber.

Abstract: There is provided a manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack. The manifold comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit. The chimney exit and said chamber inlet lie side-by-side each other such that when said open blister pocket of said blister pack is positioned adjacent thereto said airflow may be directed from the chimney exit to the chamber inlet via the open blister pocket to entrain said medicament powder and enable transport thereof in the airflow from the chamber inlet to said chamber outlet. The manifold is arranged such as to delay the emptying of the medicament powder from the blister pocket.

Abstract: A medicament dispenser device suitable for the delivery of medicament powder from an open blister pocket of at least one blister pack, the dispenser device comprises (a) a housing; (b) provided to the housing, an air inlet; (c) enclosed by the housing, a dispensing mechanism for the dispensing of medicament powder from an open blister pocket of at least one blister pack receivable thereby; and (d) associated with the dispensing mechanism and in communication with said air inlet, a manifold comprising (i) a body, (ii) the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from the chimney inlet to the chimney exit; (iii) the body further defining a chamber having a chamber inlet and a chamber exit, (iv) wherein the chimney exit and the chamber inlet lie side-by-side each other such that when the open blister pocket of the blister pack is positioned adjacent thereto the airflow will be directed from the chimney exit to the chamber inlet via the open blister pocket to entra

Abstract: A secondary internal topsheet and leg wrap structure is provided in a disposable absorbent garment such as a diaper or training pants. The leg wrap structure has a base layer, a top layer, and an elastic construction disposed inbetween. The elastic construction includes a plurality of spaced apart elastic elements that are aligned in a generally in generally parallel relation. The leg wrap structure and secondary topsheet provides for the efficient formation of a reservoir and a plurality of fluid dams each capable of capturing a quantity of fluid to minimize the occurrence of fluid leaks from the absorbent article. Methods of forming such absorbent articles are disclosed.

Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumour specific antigens (“TSAs”) and/or tumour associated antigens (“TAAs”) having shared identity with antigens in a targeted tumour. In such cases, tumour cells often are utilised as a starting point on the premise that only tumour cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and/or metastatic tumour cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumour cells.

Abstract: A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of a blister pack comprises a body, the body defining a chimney having a chimney inlet and a chimney exit for directing airflow from said chimney inlet to the chimney exit; the body further defining a chamber having a chamber inlet and a chamber exit, wherein the chimney exit and the chamber inlet lie side-by-side each other such that when the open blister pocket of the blister pack is positioned adjacent thereto the airflow is directed from the chimney exit to the chamber inlet via the open blister pocket to entrain the medicament powder and enable transport thereof in the airflow from the chamber inlet to the chamber exit, and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder.

Abstract: A laminate assembly, comprising a base sheet having at least one blister formed therein, a pharmaceutical composition displaced in the blister, a lid sheet bonded to the base sheet to form a primary seal therebetween, thus forming a primarily sealed laminate assembly; the primary sealed laminate assembly having a secondary seal formed therein, and related manufacturing method and system of manufacture.

Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells.